REDWOOD CITY, Calif.--(BUSINESS WIRE)--Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver ...
The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies ...
SAN DIEGO--(BUSINESS WIRE)--Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback